Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade

Cancer Research

Volumn 63, Issue 18, 2003, Pages 5669-5673

  Collisson, Eric A ^a,b   De, Abhijit ^a   Suzuki, Hiroyuki ^a   Gambhir, Sanjiv S ^a   Kolodney, Michael S ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAF GENE; CARCINOGENESIS; CELL SURVIVAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; GENE; GENE MUTATION; HUMAN; HUMAN CELL; LUNG METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR REGRESSION;

ANIMALS; BENZAMIDES; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; MAP KINASE KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MELANOMA; MICE; MICE, SCID; MITOGEN-ACTIVATED PROTEIN KINASES; ONCOGENE PROTEINS; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RAF; RAS PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0141508024     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chin, L., Merlino, G., and DePinho, R. A. Malignant melanoma: modern black plague and genetic black box. Genes Dev., 12: 3467-3481, 1998.
2. Howe, H. L., Wingo, P. A., Thun, M. J., Ries, L. A., Rosenberg, H. M., Feigal, E. G., and Edwards, B. K. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J. Natl. Cancer Inst., 93: 824-842, 2001.
3. Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B. A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G. J., Bigner, D. D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J. W., Leung, S. Y., Yuen, S. T., Weber, B. L., Seigler, H. F., Darrow, T. L., Paterson, H., Marais, R., Marshall, C. J., Wooster, R., Stratton, M. R., and Futreal, P. A. Mutations of the BRAF gene in human cancer. Nature (Lond.), 417: 949-954, 2002.
4. Pollock, P. M., Harper, U. L., Hansen, K. S., Yudt, L. M., Stark, M., Robbins, C. M., Moses, T. Y., Hostetter, G., Wagner, U., Kakareka, J., Salem, G., Pohida, T., Heenan, P., Duray, P., Kallioniemi, O., Hayward, N. K., Trent, J. M., and Meltzer, P. S. High frequency of BRAF mutations in nevi. Nat. Genet., 33: 19-20, 2003.
5. Jr, J. T., and McCubrey, J. A. Targeting the Raf kinase cascade in cancer therapy-novel molecular targets and therapeutic strategies. Expert Opin. Ther. Targets, 6: 659-678, 2002.
6. Zhang, B. H., and Guan, K. L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J., 19: 5429-5439, 2000.
7. Johnson, G. L., and Lapadat, R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (Wash. DC), 298: 1911-1912, 2002.
8. van't Veer, L. J., Burgering, B. M., Versteeg, R., Boot, A. J., Ruiter, D. J., Osanto, S., Schrier, P. I., and Bos, J. L. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol., 9: 3114-3116, 1989.
9. Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., Horner, J. W., 2nd, Cordon-Cardo, C., Yancopoulos, G. D., and DePinho, R. A. Essential role for oncogenic Ras in tumour maintenance. Nature (Lond.), 400: 468-472, 1999.
10. Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., and Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science (Wash. DC), 293: 876-880, 2001.
11. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Van Becelaere, K., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 5: 810-816, 1999.
12. De, A., Lewis, X. Z., and Gambhir S. S. Noninvasive imaging of lentiviral mediated reporter gene expression in living mice. Mol. Ther., 7: 681-691, 2003.
13. Wu, J. C., Sundaresan, G., Iyer, M., and Gambhir, S. S. Noninvasive optical imaging of firefly luciferase reporter gene expression in skeletal muscles of living mice. Mol. Ther., 4: 297-306, 2001.
14. Cohen, C., Zavala-Pompa, A., Sequeira, J. H., Shoji, M., Sexton, D. G., Cotsonis, G., Cerimele, F., Govindarajan, B., Macaron, N., and Arbiser, J. L. Mitogen-activated protein kinase activation is an early event in melanoma progression. Clin. Cancer Res., 8: 3728-3733, 2002.
15. Clark, E. A., Golub, T. R., Lander, E. S., and Hynes, R. O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature (Lond.), 406: 532-535, 2000.
16. Delaney, A. M., Printen, J. A., Chen, H., Fauman, E. B., and Dudley, D. T. Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352. Mol. Cell. Biol., 22: 7593-7602, 2002.
17. Koo, H. M., Van Brocklin, M., McWilliams, M. J., Leppla, S. H., Duesbery, N. S., and Woude, G. F. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc. Natl. Acad. Sci. USA, 99: 3052-3057, 2002.
18. Dai, Y., Yu, C., Singh, V., Tang, L., Wang, Z., McInistry, R., Dent, P., and Grant, S. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res., 61: 5106-5115, 2001.
19. Hood, J. D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R. A., Xiang, R., and Cheresh, D. A. Tumor regression by targeted gene delivery to the neovasculature. Science (Wash. DC), 296: 2404-2407, 2002.
20. Bernards, R., and Weinberg, R. A. A progression puzzle. Nature (Lond.), 418: 823, 2002.
21. Ramaswamy, S., Ross, K. N., Lander, E. S., and Golub, T. R. A molecular signature of metastasis in primary solid tumors. Nat. Genet., 33: 49-54, 2003.